Lee SW et al., 2021-05-17: A review of methylene blue as an analgesic. It describes the mechanisms (anti-inflammation, sodium current reduction, denervation) and the clinical use in discogenic back pain, and states plainly that the efficacy evidence is contested and that toxicity limits its use.
Moreover, we showed controversies over the efficacy of MB on CDLBP and raised also toxicity issues to look into the limitation of MB application.
Lee SW et al., 2021-05-17: A review of methylene blue as an analgesic. It describes the mechanisms (anti-inflammation, sodium current reduction, denervation) and the clinical use in discogenic back pain, and states plainly that the efficacy evidence is contested and that toxicity limits its use. Study type: narrative review. Country: South Korea (Korea University). Funders/conflicts: authors declare no commercial or financial conflicts. Gives no support for the specific percentages attributed to Dr Mihalcea; it is recorded as the best available peer-reviewed summary of the analgesic evidence and of its limits. Study type: review.
